We are live on ! Find out more
TYRA icon

Tyra Biosciences

117 hedge funds and large institutions have $500M invested in Tyra Biosciences in 2025 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 42 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

366% more call options, than puts

Call options by funds: $233K | Put options by funds: $50K

35% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 31

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

4.84% more ownership

Funds ownership: 96.07%100.91% (+4.8%)

4% more funds holding

Funds holding: 113117 (+4)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

26% less capital invested

Capital invested by funds: $676M → $500M (-$176M)

Holders
117
Holders Change
+4
Holders Change %
+3.54%
% of All Funds
1.57%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.05%
New
20
Increased
42
Reduced
31
Closed
16
Calls
$233K
Puts
$50K
Net Calls
+$183K
Net Calls Change
+$213K
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$1.68M +$1.38M +106,441 +144%
Charles Schwab
27
Charles Schwab
California
$1.53M -$84K -6,492 -4%
PAMP
28
Polar Asset Management Partners
Ontario, Canada
$1.31M +$390K +30,134 +27%
Walleye Capital
29
Walleye Capital
New York
$1.31M +$1.01M +77,762 +123%
Axa
30
Axa
France
$1.19M +$1.66M +128,189 New
ABG
31
Ally Bridge Group
New York
$997K -$878K -67,819 -39%
Wellington Management Group
32
Wellington Management Group
Massachusetts
$968K +$119K +9,228 +10%
WP
33
Woodline Partners
California
$931K +$1.3M +100,108 New
Citadel Advisors
34
Citadel Advisors
Florida
$895K +$527K +40,695 +73%
CSS
35
Cubist Systematic Strategies
Connecticut
$854K -$232K -17,904 -16%
JP Morgan Chase
36
JP Morgan Chase
New York
$795K -$72.8K -5,625 -6%
ICCON
37
Investment Counsel Company of Nevada
Nevada
$791K
Bank of America
38
Bank of America
North Carolina
$777K +$225K +17,364 +26%
Goldman Sachs
39
Goldman Sachs
New York
$725K +$180K +13,896 +22%
OC
40
Oppenheimer & Co
New York
$696K -$8.2K -634 -0.8%
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$641K +$836K +64,632 +1,497%
Two Sigma Investments
42
Two Sigma Investments
New York
$603K +$240K +18,549 +40%
State of Wisconsin Investment Board
43
State of Wisconsin Investment Board
Wisconsin
$546K -$81.9K -6,327 -10%
Victory Capital Management
44
Victory Capital Management
Texas
$522K -$6.34K -490 -0.9%
Raymond James Financial
45
Raymond James Financial
Florida
$505K -$5.68K -439 -0.8%
Renaissance Technologies
46
Renaissance Technologies
New York
$478K +$289K +22,300 +77%
Two Sigma Advisers
47
Two Sigma Advisers
New York
$466K +$489K +37,800 +307%
N
48
Nuveen
North Carolina
$465K
Point72 Asset Management
49
Point72 Asset Management
Connecticut
$461K +$476K +36,817 +288%
BHCM
50
Brevan Howard Capital Management
Jersey
$431K +$600K +46,371 New

TYRA Hedge Fund Activity: Q1 2025 in Review

117 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q1 2025, worth a combined $500M — down 26% from $676M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new TYRA positions and 16 closed out — a net gain of 4 holders — while 42 added to existing stakes and 31 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $24.5M. The largest seller was Boxer Capital Management, exiting entirely with an estimated $28.2M sold.

  • 117 institutional investors held Tyra Biosciences (TYRA) as of Q1 2025, up from 113 in Q4 2024.
  • Funds reported $500M of Tyra Biosciences stock for Q1 2025, down 26% quarter-over-quarter.
  • 20 funds opened new Tyra Biosciences positions in Q1 2025 and 16 closed out, a net change of +4 holders.
  • The largest Tyra Biosciences buyer in Q1 2025 was Vestal Point Capital, an estimated $24.5M added.
  • The largest Tyra Biosciences seller in Q1 2025 was Boxer Capital Management, an estimated $28.2M sold.

Based on aggregated 13F filings for Q1 2025.